Background Cancer patients have been reported to be at higher risk of COVID-19 complications
and deaths. We report the characteristics and outcome of patients diagnosed with …

Anti-CTLA-4 antibodies are the most involved immune checkpoint inhibitors in colitis, and the
combinations with anti-programmed death ligand 1 dramatically increase the rate of colitis. …

Background Half of breast cancers exhibit low expression levels of human epidermal
growth factor receptor 2 (HER2) and can be targeted by new antibody-drug conjugates. The …

Background Concerns have emerged about the higher risk of fatal coronavirus disease 2019
(COVID-19) in cancer patients. In this article, we review the experience of a comprehensive …

Background Ultrafast dynamic contrast-enhanced (DCE) MRI parameters are associated
with breast cancer aggressiveness. However, the role of these parameters as predictive …

Background MBD4 mutations have been reported in uveal melanomas, acute myeloid
leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a …

Background Unlike for soft tissue sarcomas, percutaneous biopsy is not validated for uterine
myometrial tumors, leading to leiomyosarcoma inadvertent morcellation and overtreatment …

Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II
trials in metastatic uveal melanoma (mUM), such combination appears frequently used in …

Simple Summary Melanin content in uveal melanoma is suspected to influence tumoral
microenvironment and antitumoral response and is related to higher risk of metastasis and death …

Background The RECIST-based response variably matches the clinical benefit of systemic
therapies for liver metastatic uveal melanoma (LMUM). The aims were to determine whether …